Nordic Nanovector: Safety Review Committee for Nordic Nanovector’s Lymrit 37-01 trial recommends dose escalation to 20 MBq/kg with Betalutin®

OSLO, Norway--()--Nordic Nanovector ASA (OSE:NANO) announces that the independent Safety Review Committee (SRC) for the ongoing Lymrit 37-01 clinical trial of Betalutin® in relapsed/refractory NHL, has recommended escalating the dose of Betalutin® in Arm 4 from 15 MBq/kg to 20 MBq/kg following pre-dosing with 100 mg/m2 lilotomab. Recruitment of 3 patients into Arm 4 to receive this new higher dosing regimen is now underway. The SRC also concluded that Arm 3 should be discontinued.

The decision follows a review by the SRC of the available safety and dosimetry data from the first cohorts of 3 patients each enrolled in Arms 3 and 4 to determine which arm should continue, if dose escalation is warranted and to what extent. Patients in Arm 3 were pre-dosed with standard rituximab immunotherapy prior to receiving 15 MBq/kg Betalutin®; patients in Arm 4 received 100 mg/m2 lilotomab prior to 15 MBq/kg Betalutin®.

The SRC recommendation for advancing Arm 4 was based on safety data demonstrating that pre-dosing with 100 mg/m2 lilotomab prior to Betalutin® reduces bone marrow toxicity as a result of lower absorbed radiation dose to this tissue. In addition, available dosimetry data from Arm 4 showed that higher pre-dosing does not prevent therapeutically relevant amounts of Betalutin® being taken up into the tumours.

Update on dose escalation in Arm 1/Phase 2

The SRC has also agreed that the company can change the treatment regimen used in Arm 1/Phase 2 to match that used in Arm 4. The dose of Betalutin® specified in Phase 2 will be increased from 15 MBq/kg to 20 MBq/kg pending review of the safety data from the first 3 patients treated in Arm 4 with 20 MBq/kg.

Escalation to the new higher dosing regimen in Arm 1/Phase 2 will also require the approval of a protocol amendment by the European regulators. The planned amendment will allow for additional patients to be enrolled into Arm 1/Phase 2, which is expected to contribute to building a more robust safety database, particularly with data from patients receiving the new higher dosing regimen.

Luigi Costa, Nordic Nanovector CEO, commented: “This is an important milestone in the development of Betalutin® in FL. We are delighted with outcome of the SRC review that provides us with the opportunity to test a higher dose of Betalutin®. We believe that the new dosing regimen will deliver an even higher efficacy than that so far observed and favourable safety, based on the evidence to date. We are confident that we will meet our goal of having a clear view on the optimum dosing regimen to use in the pivotal PARADIGME trial by the end of the first quarter 2017 as planned.”

About Lymrit 37-01

The LYMRIT 37-01 study is an ongoing Phase 1/2 open label, single injection ascending dose study investigating in three dose levels of Betalutin® and different pre-dosing regimens in patients with relapsed NHL with the aim of identifying an optimal dose regimen to take into a pivotal Phase 2 PARADIGME trial.

Updated results from the Lymrit 37-01 trial including those in Arms 3 and 4, will be presented at the 58th Annual American Society of Hematology (ASH) meeting on 3 December 2016.

About Nordic Nanovector:

Nordic Nanovector is a biotech company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology. The Company’s lead clinical-stage product opportunity is Betalutin®, the first in a new class of Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and complement current options for the treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing market worth over $12 billion by 2018.

Betalutin® comprises a tumour-seeking anti-CD37 antibody, lilotomab (previously referred to as HH1), conjugated to a low intensity radionuclide (lutetium-177). The preliminary data has shown promising efficacy and safety profile in an ongoing Phase 1/2 study in a difficult-to-treat NHL patient population. The Company is aiming at developing Betalutin® for the treatment of major types of NHL with first regulatory submission anticipated in 1H 2019.

Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets, while exploring potential distribution agreements in selected geographies. The Company is committed to developing its ARC pipeline to treat multiple selected cancer indications.

Further information about the Company can be found at www.nordicnanovector.com

This information is subject to the disclose requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

This information was brought to you by Cision http://news.cision.com

Contacts

Nordic Nanovector
IR enquiries:
Luigi Costa, +41 79 124 8601
Chief Executive Officer
or
Tone Kvåle, +47 91 51 95 76
Chief Financial Officer
ir@nordicnanovector.com
or
Media enquiries:
Mark Swallow / David Dible (Citigate Dewe Rogerson), +44 207 282 2948 / +44 207 282 2949
nordicnanovector@citigatedr.co.uk

Contacts

Nordic Nanovector
IR enquiries:
Luigi Costa, +41 79 124 8601
Chief Executive Officer
or
Tone Kvåle, +47 91 51 95 76
Chief Financial Officer
ir@nordicnanovector.com
or
Media enquiries:
Mark Swallow / David Dible (Citigate Dewe Rogerson), +44 207 282 2948 / +44 207 282 2949
nordicnanovector@citigatedr.co.uk